HC Wainwright & Co. Maintains Buy on Viridian Therapeutics, Lowers Price Target to $22

Benzinga Newsdesk www.benzinga.com Negative 46.6%

Neg 46.6% Neu 0% Pos 0%

HC Wainwright & Co. analyst Douglas Tsao maintains Viridian Therapeutics (NASDAQ:VRDN) with a Buy and lowers the price target from $34 to $22.